There were no significant differences in the clinical features between the ILD group and the non-ILD group, but the proportions of patients positive for anti-Jo-1 (27% vs. 3%, p = 0.001) and anti-Ro (47% vs. 20%, p = 0.007) were higher in the ILD group. This evidence concerns the gene CALR and interstitial lung disease.